Retrospective analysis of anti-inflammatory therapies during the first wave of COVID-19 at a community hospital

Figure 1 Kaplan Meier survival curve demonstrating increased survival in all patients who received glucocorticoid (red line) vs no glucocorticoid therapy (black line) log-rank test P < 0. 001.

Figure 2 Kaplan Meier survival curve. A: Kaplan Meier survival curve demonstrating increased survival differences in groups receiving tocilizimab + glucocorticoid (GC) (red line), GC alone (black line), tocilizumab alone (green line), and standard treatment (blue line), log rank test with Bonferroni adjustment, P < 0.001; B: Kaplan Meier survival curve comparing groups GC alone (black line), and standard treatment (red line) log rank test, P < 0.001; C: Kaplan Meier survival curve comparing groups tocilizumab + GC (black line), and standard treatment (red line) log rank test, P = 0.016; D: Kaplan Meier survival curve comparing groups tocilizumab (black line), and standard treatment (red line) log rank test, P = 0.062.